Literature DB >> 11265849

Lessons learned from the first clinical implants of the DeBakey ventricular assist device axial pump: a single center report.

G M Wieselthaler1, H Schima, A M Lassnigg, M Dworschak, R Pacher, M Grimm, E Wolner.   

Abstract

BACKGROUND: The bridge to transplantation with pulsatile mechanical assist devices became a standard procedure for patients deteriorating on the waiting list. Recently, continuous flow axial impeller pumps were introduced to clinical application offering new advantages.
METHODS: From November 1998 till September 2000, 6 male patients (mean age 53 plus or minus 11 years) with end-stage left heart failure were implanted with a DeBakey ventricular assist device (VAD) axial-flow pump for bridge to transplantation.
RESULTS: Three patients were successfully transplanted after 74, 115, and 117 days, respectively. Two other patients died after 25 and 133 days. One patient is still on the device after 108 days. Because of modification of the implantation technique after the first 2 patients, mean pump-flow within the first 3 weeks was increased from 4.3 +/- 0.6 L/min to 6.7 +/- 0.3 L/min. Patients were put on regular bicycle-ergometer training and improved their exercise capacities up to a mean maximum oxygen consumption of 20.2 mL/kg/min.
CONCLUSIONS: Initial implants of the DeBakey VAD demonstrated support properties comparable to pulsatile pumps but without significant restrictions for extended use.

Entities:  

Mesh:

Year:  2001        PMID: 11265849     DOI: 10.1016/s0003-4975(00)02636-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

Review 1.  Ventricular assist devices: destination therapy or just another stop on the road?

Authors:  Mandeep R Mehra
Journal:  Curr Heart Fail Rep       Date:  2004 Apr-May

2.  Exercise rehabilitation in ventricular assist device recipients: a meta-analysis of effects on physiological and clinical outcomes.

Authors:  Liza Grosman-Rimon; Spencer D Lalonde; Nina Sieh; Maureen Pakosh; Vivek Rao; Paul Oh; Sherry L Grace
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.